echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > European Commission approves Emgality injection stomps for preventive treatment of migraines in adults

    European Commission approves Emgality injection stomps for preventive treatment of migraines in adults

    • Last Update: 2020-06-10
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    ,pharmaceutical http://giant Eli Lilly has received big news on EU regulation
    the new drug(http://The European Commission (EC) has approved Emgality injections for the preventive treatment of adult migraines, specifically for adult patients who experience migraines for at least four days a monthEmgality will provide monthly, self-injected subcutaneous injections ofdrug(http://for adult groups of migraine patients in EuropeIn the U.S., Emgality receivedapproval from theFDA(http:// at the end of Septemberthe approval of Emgality, based on positive data from two Phase III clinical studies (EVOLVE-1, EVOLVE-2) conducted in patients with aggressive migraine (EM) and a Phase III clinical study (MONE) conducted in patients with chronic migraine (CM) the study involved 2,901 patients, the data showed that Emgality showed significant clinical and statistically significant results in reducing the number of migraine days per month across the migraine spectrum compared to placebo lilies announced plans to submit emgality's Supplemental Biologics License (sBLA) to the FDA by the end of the year for preventive treatment for adult seizure headaches , the FDA had granted Emgality a breakthrough drug for the treatment of seizure-intensive headaches
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.